Literature DB >> 20709730

Moderate postnatal hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxin.

Jen-Ruey Tang1, Gregory J Seedorf, Vincent Muehlethaler, Deandra L Walker, Neil E Markham, Vivek Balasubramaniam, Steven H Abman.   

Abstract

To determine the separate and interactive effects of fetal inflammation and neonatal hyperoxia on the developing lung, we hypothesized that: 1) antenatal endotoxin (ETX) causes sustained abnormalities of infant lung structure; and 2) postnatal hyperoxia augments the adverse effects of antenatal ETX on infant lung growth. Escherichia coli ETX or saline (SA) was injected into amniotic sacs in pregnant Sprague-Dawley rats at 20 days of gestation. Pups were delivered 2 days later and raised in room air (RA) or moderate hyperoxia (O₂, 80% O₂ at Denver's altitude, ∼65% O₂ at sea level) from birth through 14 days of age. Heart and lung tissues were harvested for measurements. Intra-amniotic ETX caused right ventricular hypertrophy (RVH) and decreased lung vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) protein contents at birth. In ETX-exposed rats (ETX-RA), alveolarization and vessel density were decreased, pulmonary vascular wall thickness percentage was increased, and RVH was persistent throughout the study period compared with controls (SA-RA). After antenatal ETX, moderate hyperoxia increased lung VEGF and VEGFR-2 protein contents in ETX-O₂ rats and improved their alveolar and vascular structure and RVH compared with ETX-RA rats. In contrast, severe hyperoxia (≥95% O₂ at Denver's altitude) further reduced lung vessel density after intra-amniotic ETX exposure. We conclude that intra-amniotic ETX induces fetal pulmonary hypertension and causes persistent abnormalities of lung structure with sustained pulmonary hypertension in infant rats. Moreover, moderate postnatal hyperoxia after antenatal ETX restores lung growth and prevents pulmonary hypertension during infancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709730      PMCID: PMC3006274          DOI: 10.1152/ajplung.00153.2010

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  71 in total

1.  Maternal preeclampsia predicts the development of bronchopulmonary dysplasia.

Authors:  Anne R Hansen; Carmen M Barnés; Judah Folkman; Thomas F McElrath
Journal:  J Pediatr       Date:  2009-12-14       Impact factor: 4.406

2.  Moderate oxygen augments lipopolysaccharide-induced lung injury in mice.

Authors:  Neil R Aggarwal; Franco R D'Alessio; Kenji Tsushima; D Clark Files; Mahendra Damarla; Venkataramana K Sidhaye; Mostafa M Fraig; Vsevolod Y Polotsky; Landon S King
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-24       Impact factor: 5.464

3.  Histologic chorioamnionitis: an occult marker of severe pulmonary hypertension in the term newborn.

Authors:  Mesfin Woldesenbet; Jeffrey M Perlman
Journal:  J Perinatol       Date:  2005-03       Impact factor: 2.521

4.  Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development.

Authors:  Sharon A McGrath-Morrow; Cecilia Cho; Chung Cho; Lijie Zhen; Daniel J Hicklin; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-02-18       Impact factor: 6.914

Review 5.  Redox regulation of lung development and perinatal lung epithelial function.

Authors:  Stephen C Land; Stuart M Wilson
Journal:  Antioxid Redox Signal       Date:  2005 Jan-Feb       Impact factor: 8.401

6.  Toll-like receptor signaling inhibits structural development of the distal fetal mouse lung.

Authors:  Lawrence S Prince; Heather I Dieperink; Victor O Okoh; German A Fierro-Perez; Roger L Lallone
Journal:  Dev Dyn       Date:  2005-06       Impact factor: 3.780

7.  Outcome of neonates less than 30 weeks gestation with histologic chorioamnionitis.

Authors:  E Dempsey; M-F Chen; T Kokottis; D Vallerand; R Usher
Journal:  Am J Perinatol       Date:  2005-04       Impact factor: 1.862

8.  Histologic chorioamnionitis and severity of illness in very low birth weight newborns.

Authors:  Claudio De Felice; Paolo Toti; Stefano Parrini; Antonio Del Vecchio; Franco Bagnoli; Giuseppe Latini; Robert J Kopotic
Journal:  Pediatr Crit Care Med       Date:  2005-05       Impact factor: 3.624

9.  Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial.

Authors:  Kristi L Watterberg; Jeffrey S Gerdes; Cynthia H Cole; Susan W Aucott; Elizabeth H Thilo; Mark C Mammel; Robert J Couser; Jeffery S Garland; Henry J Rozycki; Corinne L Leach; Conra Backstrom; Michele L Shaffer
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

10.  Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study.

Authors:  Monica M Lahra; Philip J Beeby; Heather E Jeffery
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

View more
  36 in total

1.  Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia.

Authors:  Jen-Ruey Tang; S Ananth Karumanchi; Gregory Seedorf; Neil Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-14       Impact factor: 5.464

Review 2.  Impaired pulmonary vascular development in bronchopulmonary dysplasia.

Authors:  Christopher D Baker; Steven H Abman
Journal:  Neonatology       Date:  2015-06-05       Impact factor: 4.035

3.  Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheep.

Authors:  Paul J Rozance; Gregory J Seedorf; Alicia Brown; Gates Roe; Meghan C O'Meara; Jason Gien; Jen-Ruey Tang; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-26       Impact factor: 5.464

4.  The NF-κB inhibitory proteins IκBα and IκBβ mediate disparate responses to inflammation in fetal pulmonary endothelial cells.

Authors:  Jen-Ruey Tang; Katherine A Michaelis; Eva Nozik-Grayck; Gregory J Seedorf; Marlena Hartman-Filson; Steven H Abman; Clyde J Wright
Journal:  J Immunol       Date:  2013-02-15       Impact factor: 5.422

5.  Intrauterine endotoxin-induced impairs pulmonary vascular function and right ventricular performance in infant rats and improvement with early vitamin D therapy.

Authors:  Erica Mandell; Kyle N Powers; Julie W Harral; Gregory J Seedorf; Kendall S Hunter; Steven H Abman; R Blair Dodson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-16       Impact factor: 5.464

6.  Developmental determinants and changing patterns of respiratory outcomes after preterm birth.

Authors:  Steven H Abman; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03

7.  Vitamin D treatment improves survival and infant lung structure after intra-amniotic endotoxin exposure in rats: potential role for the prevention of bronchopulmonary dysplasia.

Authors:  Erica Mandell; Gregory Seedorf; Jason Gien; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-10       Impact factor: 5.464

8.  Prenatal inflammation impairs intestinal microvascular development through a TNF-dependent mechanism and predisposes newborn mice to necrotizing enterocolitis.

Authors:  Xiaocai Yan; Elizabeth Managlia; Xiao-Di Tan; Isabelle G De Plaen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-05-24       Impact factor: 4.052

9.  Maternal diesel inhalation increases airway hyperreactivity in ozone-exposed offspring.

Authors:  Richard L Auten; M Ian Gilmour; Q Todd Krantz; Erin N Potts; S Nicholas Mason; W Michael Foster
Journal:  Am J Respir Cell Mol Biol       Date:  2011-11-03       Impact factor: 6.914

10.  Perinatal factors in neonatal and pediatric lung diseases.

Authors:  Rodney D Britt; Arij Faksh; Elizabeth Vogel; Richard J Martin; Christina M Pabelick; Y S Prakash
Journal:  Expert Rev Respir Med       Date:  2013-10-03       Impact factor: 3.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.